News

NicOx follows up private placement with rights issue

Country
France

NicOx SA of France has launched a rights issue of approximately €70 million following the successful completion of a €30 million private placement. An NDA for the company’s lead drug has been filed with the Food and Drug Administration.

Clavis Pharma partners pancreatic cancer drug candidate

Country
Norway

Clavis Pharma ASA of Norway has reached an agreement to partner its candidate drug for pancreatic cancer with a start-up oncology company in the US in a deal valued at up to $380 million. The partner is Clovis Oncology Inc of Colorado.

EMEA gives nod to new fertility treatment

Country
United Kingdom

The European Medicines Agency has given a positive opinion to a new fertility treatment developed by NV Organon of the Netherlands, now part of Merck & Co, that can be used as part of an assisted reproductive technology programme.

Should EU rules for clinical trials be revised?

Country
Belgium

The European Commission is asking companies and others involved in clinical trials  in Europe to give their views about whether the rules governing these trials should be changed.

Merck Serono to establish R&D centre in China

Country
Switzerland

Merck Serono of Geneva, Switzerland plans to invest more than €150 million in a new centre for pharmaceutical research and development in Beijing, China. The new centre will be in addition to R&D centres in Germany, Switzerland and the US.

EMEA rejects Roche’s Avastin for use in brain cancer

Country
United Kingdom

The European Medicines Agency has rejected an application from Roche to extend the use of its cancer drug Avastin (bevacizumab) for the new indication of relapsed glioblastoma. It said there was insufficient evidence of the medicine’s benefits.

Newron Pharmaceuticals raises CHF 7.9 million in private placement

Country
Italy

Newron Pharmaceuticals SpA said that it has raised CHF 7.9 million (€5.2 million) in a private share placement with institutional investors in order to finance its pipeline of new drugs. The company’s lead product is safinamide for Parkinson’s disease.

BioCity Nottingham collaborates with three US science parks

Country
United Kingdom

BioCity Nottingham, a bioscience incubator in Britain’s East Midlands, has entered into collaboration agreements with three US regional science parks to promote better transatlantic opportunities for small biotech businesses.

NicOx to raise new funds with the help of the French FSI

Country
France

NicOx SA, a publicly listed French company with a drug for osteoarthritis currently in review at the US Food and Drug Administration, has announced plans to raise fresh capital in a private share placement supported by the French FSI.